China approves ALK-Abelló's vaccination drug  

2004.03.17
The Chinese health authorities have approved registration of Alutard, an injection based vaccine against house dust mite allergy

The Chinese health authorities have approved registration of ALK-Abelló's injection based vaccine against house dust mite allergy, Alutard. The registration is based on a clinical trial carried out by Chinese specialists and ALK-Abelló at hospital allergy clinics in Guangzhou, Shenyang and Suzhou. The clinical trial demonstrated that patients with allergic asthma caused by house dust mite allergy treated with Alutard had significantly fewer allergic symptoms compared to the control group.

 

ALK-Abelló has entered a local distribution agreement with Vital BioTech which is listed on the bourse in Hong Kong and operates in China and Australia. The treatment will initially be offered to hospital allergy clinics in some of the major Chinese cities.

 

Jens Bager, managing director of ALK-Abelló says house dust mites are the most important cause of allergy in China and that he is happy ALK-Abelló now can offer vaccination treatment. The company hopes to build a satisfactory business in China based on the new activities. The news is reported by BiotechDenmark and on ALK-Abelló's website.

 

Link > ALK-Abelló 

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×